iCAN science seminar on April 17 with Dr. Florian Perner
You are warmly welcome to iCAN science seminar on
Wed 17.4.2024 at 13:30-14:30, Biomedicum 1, seminar room 1-2 or online. (Meeting ID: 648 0498 6682 Passcode: 366409)
Speaker: Dr. med. Florian Perner, Hannover Medical School, Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation
Title: Targeting oncogenic chromatin complexes: from mechanistic discoveries to clinical application
Dr. Perner received his doctorate from Otto-von-Guericke University Magdeburg in 2018. He is currently the PI of the Emmy-Noether Research Group “Translational Epigenetics”. The group studies epigenetic mechanisms in Acute Myeloid Leukemia, clonal hematopoiesis, and pre-leukemic conditions to understand the underlying basic biological principles and advance targeted epigenetic treatment strategies.
Dr. Florian Perner received the Artur-Pappenheim-Price from the German Society of Hematology and Oncology in October 2023. The Price honored his contribution to the understanding of the molecular mechanisms underlying responses of leukemia cells to treatment with inhibitors of the Menin-MLL1-Interaction.
Please see Dr. Perner’s CV for more information.
Konstantin Matjusinski (konstantin.matjusinski@helsinki.fi) will host a student get-together with Dr. Perner after the talk. Please contact Konstantin, if you are interested in joining.
If you wish to meet with Dr. Perner, please contact Mikko Myllymäki at mikko.myllymaki@helsinki.fi.
Selected publications (10 selected of last 5 years)
Perner F., Stein E.M., Wenge D.V., Singh S., Kim J., Apazidis A., Rahnamoun H., Anand D., Marinaccio C., Hatton C., Wen Y., Stone R.M., Schaller D., Mowla S., Xiao W.,10, Gamlen H.A., Stonestrom A.J., Persaud S., Ener E., Cutler J.A., Doench J.G., McGeehan G.M., Volkamer A., Chodera J.D., Nowak R.P., Fischer E.S., Levine R.L., Armstrong S.A., Cai S.F. MEN1 mutations mediate clinical resistance to Menin inhibition. 2023. Nature. 615(7954):913-919.
Soto-Feliciano Y.M.*, Sánchez-Rivera F.J.*, Perner F.*, Barrows D.W., Kastenhuber E.R., Ho Y.J., Carroll T., Xiong Y., Anand D., Soshnev A., Gates L., Beytagh M.C., Cheon D., Gu S., Liu X.S., Krivtsov A.V., Meneses M., de Stanchina E., Stone R.M., Armstrong S.A., Lowe S.W., and Allis C.D. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. 2023. Cancer Discovery, 13(1): p. 146-169. * authors contributed equally
Perner F., Schnoeder T.M., Xiong Y., Jayavelu A.K., Mashamba N., Tubio Santamaria N., Huber N., Todorova K., Hatton C., Perner B., Eifert T., Murphy C., Hartmann M., Hoell J.I., Schröder N., Brandt S., Hochhaus A., Mertens P.R., Mann M., Armstrong S.A., Mandinova A., Heidel F.H. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. 2021. Leukemia; in print
Perner F., Gadrey J.Y., Xiong Y., Hatton C., Eschle B.K., Weiss A., Stauffer F., Gaul C., Tiedt R., Perry J.A., Armstrong S.A., & Krivtsov A.V. Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts. 2020. Blood. doi:10.1182
Aubrey B.A., Cutler B.J., Bourgeois W., Donovan K.A., Gu S., Hatton C., Perlee S., Perner F., Rahnamoun H., Theall A.C.P., Henrich J.A., Zhu Q., Nowak R.P., Kim Y.J., Parvin S., Cremer A., Olsen S.N., Eleuteri N.A., Pikman Y., McGeehan G.M., Stegmaier K., Letai A., Fischer E.S., Liu X.S., & Armstrong S.A., IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. 2022. Nature Cancer, 3(5): p. 595-613.
Uckelmann H.J., Haarer E.L., Takeda R., Wong E.M., Hatton C., Marinaccio C., Perner F., Rajput M., Antonissen N.J.C., Wen Y., Yang L., Brunetti L., Chen C.W. & Armstrong S.A.. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. 2022. Cancer Discovery, CD-22-0366
Olsen S.N., Godfrey L., Healy J.P., Choi Y.A., Kai Y., Hatton C., Perner F., Haarer E.L., Nabet B., Yuan G.C. & Armstrong SA. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. 2022. Molecular Cell, 82(6): p. 1140-1155 e11.
Heikamp E.B., Henrich J.A., Perner F., Wong E.M., Hatton C., Wen Y., Barwe S.P., Gopalakrishnapillai A., Xu H., Uckelmann H.J., Takao S., Kazansky Y., Pikman Y., McGeehan G.M., Kolb E.A., Kentsis A. & Armstrong S.A. The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. 2022. Blood. 139(6):894-906
Jayavelu, A.K., Schnoeder, T.M., Perner, F., Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R., Brandt, S., Palandri, F., Schroder, N., Isermann, B., Edlich, F., Sinha, A.U., Ungelenk, M., Hubner, C.A., Zeiser, R., Rahmig, S., Waskow, C., Coldham, I., Ernst, T., Hochhaus, A., Jilg, S., Jost, P. J., Mullally, A., Bullinger, L., Mertens, P.R., Lane, S.W., Mann, M., & Heidel, F.H. (2020). Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 588(7836), 157-163.
Krivtsov, A.V., Evans, K., Gadrey, J.Y., Eschle, B.K., Hatton, C., Uckelmann, H.J., Ross, K.N., Perner, F., Olsen, S.N., Pritchard, T., McDermott, L., Jones, C.D., Jing, D., Braytee, A., Chacon, D., Earley, E., McKeever, B.M., Claremon, D., Gifford, A.J., Lee, H.J., Teicher, B.A., Pimanda, J.E., Beck, D., Perry, J.A., Smith, M.A., McGeehan, G.M., Lock, R.B., & Armstrong, S.A. (2019). A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell, 36(6), 660-673.
For more information on the seminar, please contact us at ican(at)helsinki.fi